Pressure BioSciences, Target Discovery expand strategic license agreement

Pressure BioSciences and Target Discovery announced the signing of expanded strategic technology license and supply agreements. Under these agreements, TDI now has the right to use PBI's patented and enabling Pressure Cycling Technology Platform for their planned entry into the clinical diagnostics testing market. The planned commercial diagnostic services will initially target what the companies believe are critical, unmet needs in treatment selection guidance for ovarian cancer. Until now, PBI's PCT Platform has been available on a "research-use-only" basis.

View Comments (0)